Bivalirudin: An anticoagulant option for percutaneous coronary intervention

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 2, 2004, Pages 153-162

  Bates, Eric R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acute coronary syndromes; Bivalirudin direct thrombin inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOGENESIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SYNDROME; THROMBOSIS;

EID: 2542581490     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.2.153     Document Type: Article

References (34)

1. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106, 1893-1900 (2002).
2. Weitz JI, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc. Toxicol. 3, 13-25 (2003).
3. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289, 331-342 (2003).
4. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patient data. Lancet 359, 294-302 (2002).
5. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 100, 148-152 (2002).
6. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb. Haemost. 85, 958-965 (2001).
7. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22, 1381-1389 (2002).
8. Weitz J, Hudoba M, Massel D. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86, 385-391 (1990).
9. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 407, 258-264 (2000).
10. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. J. Cardiol. 82, 12P-18P (1998).
11. Maraganore JM, Bourdon P, Jablonski J et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101 (1990).
12. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin. Pharmacol. Ther. 71, 433-439 (2002).
13. Lidon RM, Theroux P, Lesperance J et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89, 1567-1572 (1994).
14. Theroux P, Perez-Villa F, Waters D et al. Randomized, double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91, 2132-2139 (1995).
15. White HD, Aylward PE, Frey MJ. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 96, 2155-2161 (1997).
16. Lidon RM, Theroux P, Juneau M et al. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 88, 1495-1501 (1993).
17. Sharma GVRK, Lapsey D, Vita J et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am. J. Cardiol. 72, 1357-1360 (1993).
18. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischaemia (TIMI) 7 trial. Circulation 92, 727-733 (1995).
19. Cannon CP, Maraganore JM, Loscalzo J et al. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am. J. Cardiol. 71, 778-782 (1993).
20. Topol EJ, Bonan R, Jewitt D et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87, 1622-1629 (1993).
21. Lincoff AM, Kleiman NS, Kottke-Marchant K et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximaab Complications with Hirulog for Ischemic Events Trial (CACHET). Am. Heart. J. 143, 847-853 (2002).
22. Lincoff AM. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GPIIb/IIIa blockade: results of the REPLACE-1 trial. J. Am. Coll. Cardiol. 39 (Suppl. A), 16A (Abstract) (2002).
23. The HERO-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358, 1855-1863 (2001).
24. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation MI: observations from the TIMI-8 trial. Am. Heart. J. 143, 229-234 (2002).
25. Bittl JA, Chairman B, Feit F et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina. Final report reanalysis of the bivalirudin angioplasty study. Am. Heart. J. 142, 952-959 (2001).
26. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: REPLACE-2 randomized trial. JAMA 289, 853-863 (2003).
27. Antman EM. Should bivalirudin replace heparin during percutaneous coronary intervention? JAMA 289, 903-905 (2003).
28. Nallamothu B, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J. Am. Coll. Cardiol. 42, 1412-1414 (2003).
29. Cohen DJ, Lavelle T, Chen H-L et al. Cost-effectiveness of bivalirudin with provisional glycoprotein 2b/3a inhibition vs. heparin + routine glycoprotein 2b/3a inhibition for contemporary PCI: results from the REPLACE II trial. Circulation 108 (Suppl. IV), IV-570 (Abstract) (2003).
30. Mahaffey KW, Lewis BE, Wildermann NW et al. The Anticoagulant Therapy with Bivalirudin to Assist in the performance of percutaneous coronary intervention in patients with heparin-induced Thrombocytopenia (ATBAT) study: main results. J. Invas. Cardiol. 15, 611-616 (2003).
31. Kinnaird TD, Stabile E, Mintz GS et al. Incidence, predictors and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am. J. Cardiol. 92, 930-935 (2003).
32. Chew D, Bhatt D, Kimball W et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am. J. Cardiol. 92, 919-923 (2003).
33. The SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am. Heart J. 143, 952-960 (2002).
34. Merry AF, Raudkivi P, White HD et al. Anticoagulation with bivalirudin (a direct thrombin inhibitor) versus heparin. A randomized trial in OPCAB graft surgery. Anesth. Analg. 93, SCA 33 (Abstract) (2002).